A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis

Biomed Res Int. 2014:2014:785039. doi: 10.1155/2014/785039. Epub 2014 Mar 19.

Abstract

PET based tools can improve the early diagnosis of Alzheimer's disease (AD) and differential diagnosis of dementia. The importance of identifying individuals at risk of developing dementia among people with subjective cognitive complaints or mild cognitive impairment has clinical, social, and therapeutic implications. Within the two major classes of AD biomarkers currently identified, that is, markers of pathology and neurodegeneration, amyloid- and FDG-PET imaging represent decisive tools for their measurement. As a consequence, the PET tools have been recognized to be of crucial value in the recent guidelines for the early diagnosis of AD and other dementia conditions. The references based recommendations, however, include large PET imaging literature based on visual methods that greatly reduces sensitivity and specificity and lacks a clear cut-off between normal and pathological findings. PET imaging can be assessed using parametric or voxel-wise analyses by comparing the subject's scan with a normative data set, significantly increasing the diagnostic accuracy. This paper is a survey of the relevant literature on FDG and amyloid-PET imaging aimed at providing the value of quantification for the early and differential diagnosis of AD. This allowed a meta-analysis and GRADE analysis revealing high values for PET imaging that might be useful in considering recommendations.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / diagnostic imaging*
  • Alzheimer Disease / metabolism*
  • Amyloid / metabolism*
  • Glucose-6-Phosphate / analogs & derivatives*
  • Glucose-6-Phosphate / therapeutic use
  • Humans
  • Positron-Emission Tomography / methods*
  • Radiography
  • Radiopharmaceuticals / therapeutic use*

Substances

  • Amyloid
  • Radiopharmaceuticals
  • 2-fluoro-2-deoxyglucose-6-phosphate
  • Glucose-6-Phosphate